The aim of this second phase trial was to assess the treatment’s overall response rate, its toxicity in patients, the possibility of recovery of innate stem cells, and the response kinetics which is calculated by measuring M-protein concentrations in serum and urine. M-protein is associated with myeloma presence.
This research work, conducted in the frame of the PETHEMA network, has been coordinated by Hospital Clínic de Barcelona and had the participation of eight more Spanish hospitals: Hospital Germans Trias i Pujol, Hospital Clínico Salamanca, Hospital de Sant Pau, Hospital Clínico de Madrid, Hospital La Princesa, Hospital 12 de Octubre and Hospital La Fe. A total of 40 patients between 41 and 65 years with newly diagnosed multiple myeloma participated in this study. All of them underwent six treatment cycles with a 10-day break between each, and were administered Bortezomid or Dexamethasone alternately.
This study has showed very relevant facts. The first notable fact is that there was a global reduction of M-protein concentration in both urine and plasma, reflecting a global reduction of tumour cells. Thus, a highly efficient anti-myeloma effect was observed, and the post autologous transplantation response index was favourable: a 94% response, one third of which (33%) was of complete response (CR) and 22% was a very good partial response (VGPR).
Another surprising result was the speed at which the effect was achieved – i.e. the highest reduction in M-protein was detected within the first four treatment cycles. It should be mentioned that the first two cycles already caused an 82% reduction. These results set the base for further clinical trials in order to reduce the total number of previous medication cycles. A change like this in the therapeutic guidelines would not only anticipate transplantation but would also result in reduction of both economical costs and medication.
Last but not least, the observed good treatment tolerance and the ample recovery of bone marrow stem cells reinforce this therapy as the best option against multiple myeloma before autologous transplantation.
About multiple myeloma
Multiple myeloma is a type of bone marrow cancer, consisting in abnormal proliferation of plasma cells –blood cells producing antibodies that help the body’s immune system fight disease. The treatment for this kind of cancer consists of a therapy provoking a decrease in tumour cells previous to successful autologous bone marrow stem cells transplantation.
The pre-transplantation therapy used until now made patients undergo chemotherapy. This treatment form did not assure the posterior recovery of the patients’ own stem cells, while causing significantly increased toxicity levels. For this reason, a number of studies alternating drugs have been conducted during the last years, being less toxic for the patient, highly aggressive against myeloma and allowing optimal recovery of stem cells.
An example is the study that used Thalidomide and Bortezomid. In the first place the US FDA approved the use of Thalidomide combined with Dexamethasone (Rajkumar SV et al ) but the treatment only gave a slightly elevated total remission and no overall improvement was observed after transplantation. In a second case, Bortezomid was administered together with Dexamethasone (Jagannath et al ). The total remission results were notable, but toxicity levels in patients was still too high.
Hospital Clínic at ASCO
The ASCO Annual Meeting, celebrated this year in Chicago from June 01 – 05 is considered to be the world’s most important event for the whole scientific community making research on issues related to cancer, which has more than 30,000 researchers. Every year thousands of articles from all over the world are presented at ASCO, reflecting the last clinical and translational research progress within the areas of prevention, diagnosis and treatment of cancer.
This year Hospital Clínic-IDIBAPS has played an important role. First of all due to the oral presentations of Dr. Laura Rosiñol and Joan Bladé, of the Haematooncology Group of Hospital Clínic-IDIBAPS, who have presented two studies about multiple myeloma, which will mean an important progress in the treatment of this disease and second due to the presentation within the full session of Dr Jordi Bruix and Dr. Josep María Llovet from the Hepatic Oncology Group of Hospital Clínic-IDIBAPS, exposing some unprecedented results about a therapy of liver cancer.
These events strengthen Hospital Clinic’s commitment in being an oncological reference hospital not only for the development of translational research, but also for patient health care.
Àlex Argemí Saburit | alfa
New insights into the information processing of motor neurons
22.02.2017 | Max Planck Florida Institute for Neuroscience
Wintering ducks connect isolated wetlands by dispersing plant seeds
22.02.2017 | Utrecht University
In the field of nanoscience, an international team of physicists with participants from Konstanz has achieved a breakthrough in understanding heat transport
Cells need to repair damaged DNA in our genes to prevent the development of cancer and other diseases. Our cells therefore activate and send “repair-proteins”...
The Fraunhofer IWS Dresden and Technische Universität Dresden inaugurated their jointly operated Center for Additive Manufacturing Dresden (AMCD) with a festive ceremony on February 7, 2017. Scientists from various disciplines perform research on materials, additive manufacturing processes and innovative technologies, which build up components in a layer by layer process. This technology opens up new horizons for component design and combinations of functions. For example during fabrication, electrical conductors and sensors are already able to be additively manufactured into components. They provide information about stress conditions of a product during operation.
The 3D-printing technology, or additive manufacturing as it is often called, has long made the step out of scientific research laboratories into industrial...
Nature does amazing things with limited design materials. Grass, for example, can support its own weight, resist strong wind loads, and recover after being...
Nanometer-scale magnetic perforated grids could create new possibilities for computing. Together with international colleagues, scientists from the Helmholtz Zentrum Dresden-Rossendorf (HZDR) have shown how a cobalt grid can be reliably programmed at room temperature. In addition they discovered that for every hole ("antidot") three magnetic states can be configured. The results have been published in the journal "Scientific Reports".
Physicist Dr. Rantej Bali from the HZDR, together with scientists from Singapore and Australia, designed a special grid structure in a thin layer of cobalt in...
13.02.2017 | Event News
10.02.2017 | Event News
09.02.2017 | Event News
22.02.2017 | Power and Electrical Engineering
22.02.2017 | Life Sciences
22.02.2017 | Innovative Products